HTR3A and colorectal carcinoma: Wu et al. conducted a multicentre randomised clinical trial involving 112 CRC patients who were randomised in a 1:1 ratio to receive FP-based chemotherapy combined with conventional antiemetic therapy comprising a 5-HT3 antagonist and dexamethasone plus Hezhong granules or placebo.